Factor XIs: Are They the Knockout Round in Next Phase Antithrombotic Therapies?  

What You Will Learn

• Compare and contrast vitamin K agonists (VKA), direct oral anticoagulant (DOAC), and factor XI inhibitors.
• Discuss the role of factor XI in hemostasis and thrombosis.
• Summarize completed clinical trials on FXI inhibitors.
• Employ multidisciplinary approaches for developing effective care pathways.

We are grateful to these distinguished faculty who contributed to this collection:

Chair

Geoffrey Barnes, MD, MSc, FACC

Faculty

Marc Bonaca, MD, FACC 

Jean M. Connors, MD 

Robert Harrington, MD, MACC 

Kristen Bova Campbell, PHARMD, FACC 

Educational Grant Support Provided By: Supported by educational grants from the Bristol Myers Squibb and Janssen Pharmaceuticals, Inc. Alliance.

Page Launched: April 2025